Thromboplastin

Thromboplastins

Pharmacological group.

Diagnostic drugs.

* **Action** . Clinical diagnostic laboratory tool. It is a reagent for producing blood thromboplastin. When the drug is added to whole blood, lysed leukocyte mass or plasma, coagulation occurs with small amounts of circulating fibrinolytic factors, as well as with minimal antithrombin III activity. The clotting time is extended only to the extent necessary to determine the ion content of thromboplastic activity and plasma coagulability. The formed clot has stable clotting time and bleeding characteristics. ***Method of nonspecific monitoring of the effectiveness of glutamyltransferase, including the selection of the optimal inducer using RFMC as the basis for tests.** **Determination of platelet functionality in vitro using PHA agglutination** is used in the practice of clinical diagnostic laboratories mainly to solve problems of growth properties blood and functional state of platelets. Venous whole blood samples are tested for RFMK, platelet aggregation in the “Standard Test” and the “ADP Test”. Lewis and Ellwood recommended testing the aggregation effect of ADP on platelets for 5 minutes ("Standard ADP Aggregation") and for 30 minutes to detect delayed sensitivity to ADP after a 20-minute period of assessment of spontaneous